PT  - JOURNAL ARTICLE
AU  - Echave, Marta Martin
AU  - Schnack, Hugo G.
AU  - Díaz-Caneja, Covadonga M.
AU  - Pina-Camacho, Laura
AU  - Janssen, Niels
AU  - Gordaliza, Pedro M.
AU  - Kho, Kuan H.
AU  - Buimer, Elizabeth E.L.
AU  - van Haren, Neeltje E.M.
AU  - Kahn, René S.
AU  - Hulshoff Pol, Hilleke E.
AU  - Parellada, Mara
AU  - Arango, Celso
AU  - Janssen, Joost
TI  - Individualized cortical thickness asymmetry in Autism Spectrum Disorders and Schizophrenia
AID  - 10.1101/2024.11.06.24316751
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.11.06.24316751
4099  - http://medrxiv.org/content/early/2024/11/06/2024.11.06.24316751.short
4100  - http://medrxiv.org/content/early/2024/11/06/2024.11.06.24316751.full
AB  - Introduction Cortical thickness asymmetry has been proposed as a latent biomarker for Autism Spectrum Disorders (ASD) and schizophrenia (SZ). However, the degree of abnormal asymmetry at the individual level in ASD and SZ remains unclear. To investigate this, we applied normative modeling.Methods Normative means for the whole brain and regional (160 cortical parcels) cortical thickness asymmetry index (AI) were established using a training set of healthy subjects (n=4,904, 45.15% male, age range: 6-95 years), controlling for age, sex, image quality and scanner. We calculated z-scores to quantify individual deviations from the normative mean in a test set consisting of healthy controls (HCtest, n=526, 40% male), participants with ASD (n=135, 83% male) and SZ (n=287, 81% male). Regional deviance was assessed by counting the number of individuals with significant deviations below (infra-normal, z-score ≤ -1.96) or above (supra-normal, z-score ≥ 1.96) normative means in each parcel. We also evaluated individual deviance by counting the number of regions with significant deviations for each participant. A data-driven multivariate approach was employed to determine whether joint regional deviance was associated with diagnosis.Results There were no differences for deviance of whole brain AI between any of the groups. Distributions of individual deviances overlapped across all 160 regions, with only one superior temporal region in which SZ individuals showed a higher proportion of supra-normal AI values compared to HCtest (HCtest = 1.14%, SZ = 5.92%, χ2 = 15.45, PFDR< 0.05, ω = 0.14). The SZ group also had a higher average number of regions with significant deviations than HCtest (infra-normal: z = -4.21, p < 0.01; supra-normal: z = -4.33, p < 0.01). Multivariate analysis showed no association between inter-regional heterogeneity of AI and diagnosis. Results were consistent when using a higher resolution parcellation, alternative asymmetry calculations, analysis restricted to males, and after controlling for handedness and IQ.Conclusions Our findings indicate that whole brain, regional and inter-regional variability in cortical thickness AI among those with ASD is entirely accounted for by normative variation. This study challenges the utility of cortical thickness asymmetry as a biomarker for ASD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), CIBER -Consorcio Centro de Investigacion Biomedica en Red- (CB/07/09/0023), co-financed by the European Union, ERDF Funds from the European Commission, A way of making Europe, (PI16/02012, PI17/01249, PI17/00997, PI19/01024, PI20/00721, PI22/01824, PI22/01621, PI23/00625), financed by the European Union - NextGenerationEU (PMP21/00051), Madrid Regional Government (S2022/BMD-7216 AGES 3-CM), European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project COllaborative Network for European Clinical Trials For Children c4c (Grant agreement No 777389) Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET), Award Number 5P50MH115846-03 (Project FEP-CAUSAL) and Award Number 1R01MH128971-01A1 (Project SZ-aging), Fundacion Familia Alonso, and Fundacion Alicia Koplowitz. The results leading to this publication have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777394 for the project AIMS-2-TRIALS. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Cambridge University gave ethical approval for this work. Ethics committee of University Medical Center Utrecht gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.